← Patent-cliff monitor small molecule EPCLUSA SOFOSBUVIR; VELPATASVIR
Loss of exclusivity July 2034 latest FDA-listed patent expiry
Drug detail Brand name EPCLUSA Active ingredient SOFOSBUVIR; VELPATASVIR Strength 200MG;50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2020 Marketing status RX
Listed patents Patent Expires Type 11116783*PED July 2034 — 9757406*PED July 2034 — 10086011*PED July 2034 — 11116783 January 2034 product 10086011 January 2034 use U-1470 9757406 January 2034 product 8575135*PED May 2033 — 8940718*PED May 2033 — 8921341*PED May 2033 — 8921341 November 2032 substance, product 8575135 November 2032 substance, product 8940718 November 2032 substance, product 8618076*PED June 2031 — 9284342*PED March 2031 — 8618076 December 2030 substance, product 9284342 September 2030 substance, product 7964580*PED September 2029 — 8889159*PED September 2029 — 8633309*PED September 2029 — 7964580 March 2029 substance, product 8633309 March 2029 substance, product 8889159 March 2029 product 8580765*PED September 2028 — 8735372*PED September 2028 — 9085573*PED September 2028 — 8334270*PED September 2028 — 8334270 March 2028 substance, product 8735372 March 2028 use U-1470 8580765 March 2028 substance, product 9085573 March 2028 substance, product
Regulatory exclusivity Code Expires PED September 2027 ODE-293 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.